What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Eli Lilly and Company's financial results for the third quarter and the first nine months of 2015, which ended on September 30, 2015.

What are non-GAAP financial measures, and why does Lilly use them?

Non-GAAP financial measures are financial metrics that are not prepared in accordance with Generally Accepted Accounting Principles (GAAP). Lilly uses them to exclude certain items that may be volatile or difficult to predict, such as amortization of intangibles from acquisitions, to provide investors with a clearer view of the company's ongoing operational performance and to facilitate period-over-period comparisons.

Should investors rely solely on the non-GAAP financial measures?

No, investors should consider these non-GAAP measures in addition to, and not as a substitute for or superior to, the financial performance measures prepared in accordance with GAAP. Lilly uses them to provide supplemental insights into its business.

What specific items are excluded from Lilly's non-GAAP reporting?

Lilly's non-GAAP financial measures typically exclude the impact of significant acquisitions and divestitures, including the amortization of intangible assets primarily associated with acquired or licensed marketed products. They may also exclude other items that are highly variable, difficult to predict, and substantial in size.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on October 22, 2015, to report its third quarter and nine-month financial results for the period ended September 30, 2015. The filing includes a press release detailing these results and references a teleconference held for analysts and media to discuss the performance. A key aspect of the reporting is Lilly's use of non-GAAP financial measures, which management believes offer investors a clearer view of ongoing operations by excluding items like amortization of intangibles, acquisitions, divestitures, and other unpredictable or significant items. These non-GAAP measures are presented to aid in meaningful period-over-period comparisons and trend identification, which could otherwise be obscured by GAAP reporting. While these adjusted figures are presented as supplemental information to GAAP, Lilly emphasizes that they should be considered alongside, not as a substitute for, GAAP-prepared financial performance measures. The company also noted that its future earnings guidance is subject to adjustments for similar factors that may be difficult to quantify prospectively.

Key Highlights

1Eli Lilly announced its third quarter and nine-month 2015 financial results on October 22, 2015.
2The company held a teleconference and webcast to discuss these results with analysts and the media.
3Lilly utilizes non-GAAP financial measures, such as non-GAAP net income and earnings per share, in its reporting.
4These non-GAAP measures exclude certain items like amortization of intangibles, acquisitions, and divestitures.
5The company believes non-GAAP measures provide useful insights for investors to evaluate ongoing operations and identify trends.
6Lilly stresses that non-GAAP measures are supplemental to GAAP and should not be considered a substitute.
7Prospective earnings guidance may be subject to adjustments due to factors that are difficult to quantify.

ELI LILLY & Co 8-K Report, Financial Results (Oct 22, 2015)

Summary

Key Highlights

Frequently Asked Questions